RESUMEN
Baclofen (Lioresal) is a derivative of gamma-aminobutyric acid and is used in both adults and children mainly for symptomatic treatment of muscle spasticity. It is absorbed completely from the gastrointestinal tract, metabolized minimally in the liver and is excreted almost unchanged by the kidneys. Being lipophilic it can cross the blood-brain barrier easily. Baclofen overdose can result in life threatening complications such as respiratory failure, metabolic encephalopathy, seizures, deep coma and autonomic instability leading to hypertension and bradycardia.1-5 The literature on oral baclofen overdose in young children is very sparse. Here we report a 2-year-old-girl who was found by her parents after an accidental ingestion of her father's baclofen. The child presented with respiratory failure, coma, hypotonia and bradycardia. The patient was managed conservatively; mechanically ventilated for 16 hours and was discharged home after 48 hours with no sequelae.
Asunto(s)
Baclofeno , Coma , Relajantes Musculares Centrales , Insuficiencia Respiratoria , Adulto , Baclofeno/envenenamiento , Preescolar , Coma/inducido químicamente , Sobredosis de Droga/terapia , Femenino , Humanos , Relajantes Musculares Centrales/envenenamiento , Insuficiencia Respiratoria/inducido químicamenteRESUMEN
INTRODUCTION AND OBJECTIVES: Baclofen is a drug used mainly to treat muscle spasticity. Its overdose can lead to life-threatening clinical symptoms, including acute respiratory failure requiring mechanical ventilation. The aim of this study was to assess the prevalence of selected clinical symptoms associated with baclofen poisoning comparing to an ingested dose. MATERIAL AND METHODS: 60 cases of oral baclofen poisoning were analyzed. Gender, age distribution, and correlation between the dose of ingested baclofen were studied, as well as and following clinical parameters: degree of altered consciousness, heart rate, blood pressure, presence of acute respiratory failure, duration of mechanical ventilation, and presence of psychotic symptoms. RESULTS: The study found statistically significant correlations between dosage of ingested baclofen and presence of acute respiratory failure, as well as duration of mechanical ventilation. No statistically significant correlations were found between the dose of ingested baclofen and presence of hypertension, bradycardia, acute psychotic symptoms, or level of consciousness disturbance. However, it was found that patients who suffered from hypertension, bradycardia, and altered mental status ingested a larger dose of baclofen. CONCLUSIONS: There is a statistically significant correlation between the dose of ingested baclofen and the presence of acute respiratory failure, and duration of mechanical ventilation. Patients who have taken a single dose of baclofen of 200 mg, or higher, should be managed in centres able to provide continuous monitoring of life functions. Those with a higher level of a single dose of baclofen ingestion (>500 mg), should be hospitalized in a Toxicology Unit or Intensive Care Unit able to provide airway support and mechanical ventilation.
Asunto(s)
Baclofeno/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Insuficiencia Respiratoria/etiología , Adolescente , Adulto , Factores de Edad , Baclofeno/administración & dosificación , Presión Sanguínea/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Relajantes Musculares Centrales/administración & dosificación , Insuficiencia Respiratoria/fisiopatología , Adulto JovenRESUMEN
A method of identification and quantitative determination of baclofen in blood by HPLC with mass spectrometry detection has been developed. It is characterized by high sensitivity, specificity, linearity, accuracy, reproducibility, and a low detection for quantitative determination. The method has been used for diagnostics of acute baclofen poisoning in patients.
Asunto(s)
Baclofeno/sangre , Análisis Químico de la Sangre/métodos , Relajantes Musculares Centrales/sangre , Baclofeno/envenenamiento , Estudios de Casos y Controles , Cromatografía Líquida de Alta Presión/métodos , Humanos , Espectrometría de Masas/métodos , Relajantes Musculares Centrales/envenenamiento , Sensibilidad y EspecificidadAsunto(s)
Baclofeno/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Adulto , Anciano , Baclofeno/farmacocinética , Cuidados Críticos , Sobredosis de Droga , Femenino , Francia , Hemofiltración , Humanos , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Relajantes Musculares Centrales/farmacocinética , Convulsiones/inducido químicamente , Intento de SuicidioAsunto(s)
Baclofeno/sangre , Baclofeno/envenenamiento , Monitoreo de Drogas/métodos , Hemiplejía/tratamiento farmacológico , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/envenenamiento , Adulto , Baclofeno/farmacocinética , Biomarcadores/sangre , Femenino , Humanos , Relajantes Musculares Centrales/farmacocinética , Intoxicación/sangre , Intoxicación/diagnóstico , Intoxicación/terapia , Valor Predictivo de las Pruebas , Intento de Suicidio , Factores de Tiempo , Resultado del TratamientoRESUMEN
The objective of the present study was to select and develop simpler methods for the quantitative determination of baclofen in blood with the use of HPLC and tandem MS (MS-MS) techniques and its qualitative determination in cadaveric organs by the GC/MS technique. These mathods were shown to be suitable for the purpose of forensic medical analysis, clinical, toxicological, and therapeutic monitoring. The special emphasis is laid on the methods used to investigate the biological materials obtained from the subjects who died from baclofen intoxication.
Asunto(s)
Baclofeno/análisis , Toxicología Forense/métodos , Relajantes Musculares Centrales/análisis , Suicidio , Adulto , Baclofeno/sangre , Baclofeno/farmacocinética , Baclofeno/envenenamiento , Cromatografía Líquida de Alta Presión , Resultado Fatal , Femenino , Toxicología Forense/instrumentación , Humanos , Límite de Detección , Hígado/metabolismo , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/envenenamiento , Intoxicación/sangre , Intoxicación/etiología , Intoxicación/metabolismo , Reproducibilidad de los Resultados , Espectrometría de Masas en Tándem , Distribución TisularRESUMEN
INTRODUCTION: Tolperisone is a centrally acting muscle relaxant that acts by blocking voltage-gated sodium and calcium channels. There is a lack of information on the clinical features of tolperisone poisoning in the literature. The aim of this study was to investigate the demographics, circumstances and clinical features of acute overdoses with tolperisone. METHODS: An observational study of acute overdoses of tolperisone, either alone or in combination with one non-steroidal anti-inflammatory drug in a dose range not expected to cause central nervous system effects, in adults and children (< 16 years), reported to our poison centre between 1995 and 2013. RESULTS: 75 cases were included: 51 females (68%) and 24 males (32%); 45 adults (60%) and 30 children (40%). Six adults (13%) and 17 children (57%) remained asymptomatic, and mild symptoms were seen in 25 adults (56%) and 10 children (33%). There were nine adults (20%) with moderate symptoms, and five adults (11%) and three children (10%) with severe symptoms. Signs and symptoms predominantly involved the central nervous system: somnolence, coma, seizures and agitation. Furthermore, some severe cardiovascular and respiratory signs and symptoms were reported. The minimal dose for seizures and severe symptoms in adults was 1500 mg. In 11 cases the latency between the ingestion and the onset of symptoms was known and was reported to be 0.5-1.5 h. CONCLUSIONS: The acute overdose of tolperisone may be life-threatening, with a rapid onset of severe neurological, respiratory and cardiovascular symptoms. With alternative muscle relaxants available, indications for tolperisone should be rigorously evaluated.
Asunto(s)
Sobredosis de Droga/diagnóstico , Relajantes Musculares Centrales/envenenamiento , Centros de Control de Intoxicaciones , Intoxicación/diagnóstico , Tolperisona/envenenamiento , Enfermedad Aguda , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/efectos adversos , Sistema Cardiovascular/efectos de los fármacos , Sistema Cardiovascular/fisiopatología , Sistema Nervioso Central/efectos de los fármacos , Sistema Nervioso Central/fisiopatología , Niño , Preescolar , Sobredosis de Droga/mortalidad , Sobredosis de Droga/fisiopatología , Sobredosis de Droga/terapia , Femenino , Humanos , Lactante , Pulmón/efectos de los fármacos , Pulmón/fisiopatología , Masculino , Persona de Mediana Edad , Intoxicación/mortalidad , Intoxicación/fisiopatología , Intoxicación/terapia , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Factores de Riesgo , Índice de Severidad de la Enfermedad , Suiza , Factores de Tiempo , Adulto JovenRESUMEN
PURPOSE: Overdose with baclofen, a derivative of the inhibitory neurotransmitter γ-aminobutyric acid, may lead to severe respiratory and central nervous system depression and can be life-threatening. Prolonged half-lives of baclofen, of up to 34 h, have been reported in patients after overdose. Hemodialysis has proven to be a successful approach to improve clearance of baclofen, but the value of continuous venovenous hemofiltration (CVVH) is unclear. We applied CVVH in a patient with acute baclofen overdose. METHODS: Pharmacokinetic measurements of baclofen in serum and hemofiltrate were made at six time points after hospital admission. Baclofen concentration-time data were analyzed using non-compartmental methods, and the relative contribution of clearance by hemofiltration to total baclofen clearance was calculated. RESULTS: Baclofen concentrations in serum varied between 1.81 and 0.05 mg/L. Concentrations of baclofen in hemofiltrate were within the same range (between 0.74 and 0.05 mg/L), and the elimination half-life during hemofiltration was estimated at 4.8 h. Total clearance and clearance via hemofiltration were estimated at 6.6 and 2.4 L/h, indicating that clearance could be increased by approximately 57 % by applying hemofiltration. CONCLUSIONS: The presented case demonstrates the usefulness of CVVH in the treatment of baclofen overdose and indicates that CVVH can be used as an alternative to hemodialysis in patients with overdose of baclofen.
Asunto(s)
Baclofeno , Sobredosis de Droga/cirugía , Hemofiltración , Baclofeno/sangre , Baclofeno/farmacocinética , Baclofeno/envenenamiento , Humanos , Tasa de Depuración Metabólica , Persona de Mediana Edad , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacocinética , Relajantes Musculares Centrales/envenenamientoRESUMEN
A 55-year-old woman presented to the emergency department following an episode of severe visual impairment, headache, dizziness and confusion. The patient had been taking quinine sulfate as long-term medication for leg cramps. During an episode of sleepwalking, the patient had taken an overdose of quinine sulfate. Following a thorough investigation and assessment, a diagnosis of ocular quinine toxicity was made. We present this case and highlight the risks of quinine prescription.
Asunto(s)
Sobredosis de Droga , Oftalmopatías/inducido químicamente , Calambre Muscular/tratamiento farmacológico , Relajantes Musculares Centrales/envenenamiento , Quinina/envenenamiento , Sonambulismo , Diagnóstico Diferencial , Oftalmopatías/diagnóstico , Femenino , Humanos , Persona de Mediana Edad , Relajantes Musculares Centrales/uso terapéutico , Quinina/uso terapéuticoAsunto(s)
Alcoholismo/complicaciones , Baclofeno/envenenamiento , Sobredosis de Droga/complicaciones , Insuficiencia Renal/complicaciones , Alcoholismo/diagnóstico , Baclofeno/administración & dosificación , Baclofeno/efectos adversos , Relación Dosis-Respuesta a Droga , Sobredosis de Droga/diagnóstico , Humanos , Masculino , Persona de Mediana Edad , Relajantes Musculares Centrales/administración & dosificación , Relajantes Musculares Centrales/envenenamiento , Insuficiencia Renal/diagnósticoRESUMEN
OBJECTIVE: To identify dogs and cats with baclofen toxicosis and characterize the patient population, clinical signs, and outcome. DESIGN: Retrospective case series. ANIMALS: 140 dogs and 5 cats with baclofen toxicosis. PROCEDURES: An animal poison control center electronic database was reviewed from November 2004 through April 2010 to identify dogs and cats with baclofen toxicosis. Information on signalment, clinical signs, and amount of baclofen ingested was obtained. Clinical signs were categorized as CNS, gastrointestinal, general malaise, cardiovascular, respiratory, or urogenital. Follow-up communications were performed to determine overall outcome. RESULTS: Dogs had a median age of 0.67 years (range, 0.1 to 15 years) and cats of 1 year (range, 0.7 to 16 years). Of 145 patients, 133 (92%) developed clinical signs of baclofen toxicosis. A total of 259 signs fell within defined categories: CNS (121/259 [46.7%]), gastrointestinal (69/259 [26.6%]), general malaise (27/259 [10.4%]), cardiovascular (23/259 [8.9%]), respiratory (14/259 [5.4%]), and urogenital (5/259 [1.9%]). For 68 dogs with known survival status, survival rate was 83.8% (57/68); of these dogs, the amount of baclofen ingested was known for 53 (46 survivors and 7 nonsurvivors). Amount of baclofen ingested was significantly lower in survivor dogs (median, 4.2 mg/kg [1.91 mg/lb]; range, 0.61 to 61 mg/kg [0.28 to 27.7 mg/lb]), compared with nonsurvivor dogs (median, 14 mg/kg [6.4 mg/lb]; range, 2.3 to 52.3 mg/kg [1.04 to 23.77 mg/lb]. Of 5 cats, 2 survived, 1 died, and 2 had unknown outcomes. CONCLUSIONS AND CLINICAL RELEVANCE: Clinical signs of baclofen toxicosis occurred in most patients, with the CNS being the system most commonly affected.
Asunto(s)
Baclofeno/envenenamiento , Enfermedades de los Gatos/inducido químicamente , Enfermedades de los Perros/inducido químicamente , Relajantes Musculares Centrales/envenenamiento , Animales , Gatos , Perros , Femenino , Masculino , Centros de Control de Intoxicaciones , Estudios RetrospectivosRESUMEN
INTRODUCTION: Carisoprodol, a frequently used muscle relaxant, can cause potentially fatal intoxications. Conversion to its active metabolite meprobamate is almost solely mediated by cytochrome P450 2C19 (CYP2C19), and mutations in this enzyme could have significant effects on serum concentrations. The objective of this study was to investigate the role of CYP2C19 genetics in mortalities due to carisoprodol intoxication. METHODS: The frequencies of CYP2C19 variant alleles were compared between the study group (n = 75) and two control groups, i.e. (1) deaths where carisoprodol was detected in the blood of the deceased, but intoxication was not the cause of death (control group A, n = 38), and (2) a healthy population not using carisoprodol (control group B, n = 185). In the study group and control A, the concentrations of carisoprodol and meprobamate were compared between the different genotype subgroups. RESULTS: The variant allele frequencies of CYP2C19 did not differ significantly between the study group and control groups. Moreover, no statistically significant difference in the concentrations of carisoprodol and meprobamate between the different genotype subgroups was found. CONCLUSIONS: This study finds no evidence for an important association between CYP2C19 genetics and mortality risk of carisoprodol. Other factors, such as co-administration with other drugs, likely play a more important role.
Asunto(s)
Hidrocarburo de Aril Hidroxilasas/genética , Carisoprodol/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Polimorfismo Genético , Alelos , Hidrocarburo de Aril Hidroxilasas/metabolismo , Autopsia , Biotransformación , Carisoprodol/sangre , Carisoprodol/farmacocinética , Causas de Muerte , Citocromo P-450 CYP2C19 , Frecuencia de los Genes , Estudios de Asociación Genética , Humanos , Meprobamato/sangre , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacocinética , Noruega/epidemiología , RiesgoRESUMEN
Carisoprodol is a therapeutic and occasionally abused centrally acting muscle relaxant. We compare central blood and liver concentrations of carisoprodol and the metabolite meprobamate to concentrations in peripheral blood in 11 medical examiner cases. Specimens were initially screened for alcohol and simple volatiles by gas chromatography (GC)-flame ionization detection headspace analysis, enzyme-linked immunosorbent array for drugs of abuse, and therapeutic drugs by GC-mass spectrometry (MS). Carisoprodol, when detected by the therapeutic drug screen, was confirmed and quantified by a specific GC-MS procedure. The results suggest that when ingested with other medications, carisoprodol may be a contributing factor in death, even when present at therapeutic concentrations. Considering the cases studied, together with previously published therapeutic and fatal concentrations, blood carisoprodol concentrations greater than 15 mg/L and liver concentrations greater than 50 mg/kg may be considered excessive and potentially fatal. Carisoprodol central blood to peripheral blood ratios averaged 1.31 + 0.33 (mean ± standard deviation), and liver to peripheral blood, 2.83 ± 1.51. Meprobamate central blood to peripheral blood ratios averaged 0.92 ± 0.22, and liver to peripheral blood, 1.25 ± 0.69. The low liver to peripheral blood ratio (less than 5), taken together with the low central blood to peripheral blood ratio, is an indicator that both carisoprodol and meprobamate lack the potential to exhibit postmortem redistribution.
Asunto(s)
Carisoprodol/envenenamiento , Meprobamato/envenenamiento , Relajantes Musculares Centrales/envenenamiento , Detección de Abuso de Sustancias/métodos , Trastornos Relacionados con Sustancias/diagnóstico , Carisoprodol/sangre , Carisoprodol/farmacocinética , Diagnóstico , Toxicología Forense/métodos , Cromatografía de Gases y Espectrometría de Masas , Humanos , Hígado/metabolismo , Meprobamato/sangre , Meprobamato/farmacocinética , Relajantes Musculares Centrales/sangre , Relajantes Musculares Centrales/farmacocinética , Cambios Post Mortem , Trastornos Relacionados con Sustancias/sangre , Suicidio , Distribución TisularRESUMEN
BACKGROUND: Intrathecal baclofen (ITB) is an effective and well-tolerated treatment for patients with severe spasticity. Intoxications are rare and usually iatrogenic, with reported intrathecal boluses varying between 0.050 and 30 mg. METHODS: We here report the case of a 47-year-old woman with severe spastic paraplegia due to multiple sclerosis who, during a routine filling procedure, accidentally received a bolus of 60 mg ITB because of injection into the side-port instead of the reservoir of her ITB pump (Archimedes(®), Codman, Germany). RESULTS: After a short period of dizziness, she lost consciousness and stopped breathing. She was immediately intubated, mechanically ventilated, and admitted to the intensive care unit. As specific treatment, she received cerebrospinal fluid drainage through a newly implanted lumbar catheter. A series of generalized and complex partial seizures were treated with levetiracetam and lacosamide. Acute autonomic dysfunction with episodic arterial hypo- and hypertensions was controlled by catecholamines and clonidine, respectively. Recurrent hyperthermia, however, responded neither to drugs nor to physical treatment. After 3 weeks, the patient was discharged without any relevant new neurologic signs or symptoms. CONCLUSIONS: This case demonstrates that even excessive doses of ITB can let the patients survive without sequelae if treated promptly and offensively. A pertinent problem during detoxification is the question of when to restart ITB to avoid drug withdrawal.
Asunto(s)
Baclofeno/envenenamiento , Cuidados Críticos/métodos , Bombas de Infusión Implantables/efectos adversos , Relajantes Musculares Centrales/envenenamiento , Paraplejía/tratamiento farmacológico , Baclofeno/administración & dosificación , Femenino , Humanos , Inyecciones Espinales , Persona de Mediana Edad , Esclerosis Múltiple/complicaciones , Relajantes Musculares Centrales/administración & dosificación , Paraplejía/etiología , Síndrome de Abstinencia a Sustancias/terapiaRESUMEN
Tolperisone (Mydocalm) is a centrally acting muscle relaxant with few sedative side effects that is used for the treatment of chronic pain conditions. We describe three cases of suicidal tolperisone poisoning in three healthy young subjects in the years 2006, 2008 and 2009. In all cases, macroscopic and microscopic autopsy findings did not reveal the cause of death. Systematic toxicological analysis (STA) including immunological tests, screening for volatile substances and blood, urine and gastric content screening by GC-MS and HPLC-DAD demonstrated the presence of tolperisone in all cases. In addition to tolperisone, only the analgesics paracetamol (acetaminophen), ibuprofen and naproxen could be detected. The blood ethanol concentrations were all lower than 0.10 g/kg. Tolperisone was extracted by liquid-liquid extraction using n-chlorobutane as the extraction solvent. The quantification was performed by GC-NPD analysis of blood, urine and gastric content. Tolperisone concentrations of 7.0 mg/l, 14 mg/l and 19 mg/l were found in the blood of the deceased. In the absence of other autopsy findings, the deaths in these three cases were finally explained as a result of lethal tolperisone ingestion. To the best of our knowledge, these three cases are the first reported cases of suicidal tolperisone poisonings.